Medical Condition News

RSS

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced interim study results that showed its doxorubicin prodrug INNO-206 demonstrated statistically significant anti-tumor activity in human myeloma tumor cells growing in immune-deficient mice compared to a control group, while exhibiting significantly less toxicity than doxorubicin even though INNO-206 was administered at much higher doses.

3 May 2010

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Acucela, a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that Ryo Kubota, M.D., Ph.D., Acucela's chairman, president and chief executive officer, has been invited to participate in Retina International's annual Scientific & Medical Advisory Board meeting being held in Fort Lauderdale, Florida on May 3, 2010.

3 May 2010

Today's Opinions and Editorials: The end of insurance rescissions, lessons from the health care rollout and the deficit panel's tough decisions

A lot of people laughed when Sue Lowden, the Nevada Republican running for the U.S. Senate, suggested last month that people start paying for their medical care with chickens. I didn't (Jonathan Cohn, 5/3).

3 May 2010

Computer-based system automatically tracks radiation dose exposure in patients receiving CT scan

Researchers have developed a computer-based system that can automatically track patient-specific radiation dose exposure (based on a patient's size and weight) on every patient that receives a computed tomography (CT) scan, providing patients with a way to start tracking their cumulative health care-related radiation exposure, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

3 May 2010

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced an amendment to its 2005 collaboration agreement with AstraZeneca expanding the TC-5619 development program. In addition to the current development of TC-5619 in cognitive dysfunction in schizophrenia (CDS), the amended terms provide for parallel development in attention deficit/hyperactivity disorder (ADHD) and potentially Alzheimer's disease.

3 May 2010

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

ImmunoCellular Therapeutics announced today it has filed an orphan drug application with the U.S. Food and Drug Administration (FDA) for its cancer treatment candidate ICT-107. ICT-107 is a dendritic-cell based cancer vaccine product which targets glioblastoma multiforme (GBM), the most prevalent, aggressive and malignant form of primary brain tumors.

3 May 2010

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has successfully completed enrollment and treatment of the last patient in its Phase I clinical trial of CUDC-101, Curis' first-in-class HDAC, EGFR and HER2 inhibitor.

3 May 2010

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

With summer right around the corner, more people will be spending time outdoors and UV protection will be top of mind. Unfortunately, most people think about the protection of their skin, when they should also be considering the safety of their eyes. In fact, according to the American Optometric Association's (AOA) American Eye-Q® survey, only one-third of Americans said UV protection is the most important factor they consider when purchasing sunglasses.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

Ethicon Endo-Surgery today announced that the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system, was granted a CE Mark for the European Union for routine colonoscopy and screening of the upper gastrointestinal tract (EGD procedures), and Health Canada granted regulatory approval for the SEDASYS® System for use by healthcare professional teams during routine colonoscopy.

3 May 2010

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Abbott announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for CREON® (pancrelipase) Delayed-Release Capsules that now includes dosing guidance in the prescribing information specific to patients with limited production of enzymes in the pancreas (exocrine pancreatic insufficiency) due to chronic pancreatitis (CP) or removal of the pancreas (pancreatectomy). Prior to this FDA approval, dosing guidance for medications such as CREON was based on patients with cystic fibrosis.

3 May 2010

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Omeros Corporation today announced additional data from a Phase 2 trial of OMS103HP, its PharmacoSurgery™ product candidate for arthroscopy, showing that patients treated with OMS103HP during arthroscopic meniscectomy surgery achieved statistically significant clinical benefits.

3 May 2010

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

Clinical Data, Inc., and Santen Pharmaceutical Co., Ltd., today announced that Santen has exercised its option to license Clinical Data's highly selective adenosine A2A agonist compound, ATL313, for the development of topical treatments for certain ophthalmic diseases, including glaucoma. ATL313, a promising late-stage preclinical compound, has shown significant pharmacological effects in vivo and has been nominated as a clinical candidate.

From Santen Pharmaceutical Co., Ltd. 3 May 2010

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) today announced results from pivotal phase 3 studies of azilsartan medoxomil (development code: TAK-491), an angiotensin II receptor blocker (ARB), demonstrating greater 24-hour systolic blood pressure (SBP) reduction compared to commonly prescribed ARBs olmesartan medoxomil and valsartan.

3 May 2010

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

To coincide with Skin Cancer Awareness Month, the AVEENO Brand announces its third-year partnership with The Skin Cancer Foundation for the Road to Healthy Skin Tour, a program that has been instrumental in educating people nationwide about skin cancer detection and prevention. This year, the Tour will visit over 80 locations through September.

3 May 2010

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced results of a 230 patient Phase 2 proof-of-concept study evaluating topical SAR 1118 ophthalmic solution in the treatment of aqueous deficient dry eye (keratoconjunctivitis sicca).

3 May 2010

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

PolyTouch Medical Ltd., a leading developer of laparoscopic hernia mesh placement technologies, today announced that it has filed a Premarket 510(k) Application with the US Food and Drug Administration for PatchAssist, an Innovative Laparoscopic Mesh Deployment and Placement Device that enables accurate mesh placement in laparoscopic ventral hernia repair potentially reducing procedure time by 30%-50%.

3 May 2010

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

A recent study determined that African-Americans were less likely to have a varus thrust, but more likely to have valgus thrust than Caucasians. Varus thrust is visualized during gait as the worsening or abrupt onset of varus (bow-legged) alignment as the leg accepts weight, with a return to less varus and more neutral alignment during lift-off of the foot and the swing phase of gait.

3 May 2010

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Stimatix GI, located in the Misgav Venture Accelerator, has reported encouraging interim results in its animal trials of the AOS-C1000 artificial sphincter, designed to provide stoma patients with a new means of bowel control.

3 May 2010

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

Raptor Pharmaceutical Corp., announced positive Phase 2a clinical trial results from its pilot study of delayed-release cysteamine bitartrate in 11 adolescent patients with non-alcoholic steatohepatitis, a progressive form of liver disease believed to affect 5% to 11% of the U.S. population. The results were presented at the Digestive Disease Week 2010 conference in New Orleans, LA on May 2, 2010.

3 May 2010

Medical Condition News

Interim study results demonstrate anti-tumor activity of CytRx's INNO-206 in myeloma tumor cells

Acucela to present data on ACU-4429 oral visual cycle modulator for dry AMD at Retina International meeting

Today's Opinions and Editorials: The end of insurance rescissions, lessons from the health care rollout and the deficit panel's tough decisions

Computer-based system automatically tracks radiation dose exposure in patients receiving CT scan

Targacept, AstraZeneca expand TC-5619 development program to include ADHD, Alzheimer's disease

ImmunoCellular Therapeutics seeks FDA orphan drug status for ICT-107 dendritic-cell based vaccine for GBM

Curis completes enrollment in Phase I clinical trial of CUDC-101 HDAC, EGFR and HER2 inhibitor

Protect eyes from sun's UV rays to decrease risk of eye diseases, disorders

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Ethicon Endo-Surgery SEDASYS CAPS system receives European Union CE Mark, Health Canada approval

FDA approves Abbott's CREON sNDA including dosing guidance for treating EPI due to CP, pancreatectomy

Omeros announces additional data from Phase 2 trial of OMS103HP for arthroscopic meniscectomy surgery

Santen licenses Clinical Data's ATL313 agonist compound for development of ophthalmic treatments

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

AVEENO Brand partners with The Skin Cancer Foundation for Road to Healthy Skin Tour program

SARcode presents positive results from Phase 2 study of SAR 1118 ophthalmic solution at Dry Eye Summit

PolyTouch Medical files Premarket 510(k) application for PatchAssist laparoscopic mesh deployment device

African-Americans less likely to have varus thrust, more likely to have valgus thrust than Caucasians

Stimatix reports interim results from artificial sphincter trial for restoring bowel control in people with stoma

Raptor Pharmaceutical presents positive results from Phase 2a trial of DR cysteamine bitartrate for NASH

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News